The omicro_老虎社区_美港股上老虎

2021-12-26

The omicron variant of the SARS-CoV-2 virus, discovered just a few weeks ago, is poised to dominate Covid-19 cases around the world. It’s a stunning new twist to the pandemic saga that has countries scrambling to prepare. In places like South Africa and the United Kingdom where omicron has been spreading fast, Covid-19 cases have doubled every three days or less. This includes people who were previously infected or vaccinated against Covid-19.

Japan health panel approves Merck's oral COVID-19 treatment

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

RodBeard
2021-12-27
RodBeard
Don't worry. The epidemic will be completely improved in 2022. Give up vaccine stocks and buy tourism stocks.
RubyPulitzer
2021-12-27
RubyPulitzer
Vaccination benefits everyone in the world. The global economy needs recovery.
RonaldNixon
2021-12-27
RonaldNixon
Omicron's influence is growing. I am so worried.

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698540563,"tweetId":"698540563","gmtCreate":1640478518761,"gmtModify":1640482742135,"author":{"id":4092458811577680,"idStr":"4092458811577680","authorId":4092458811577680,"authorIdStr":"4092458811577680","name":"PearlynCSY","avatar":"https://static.tigerbbs.com/b3e9fe7af061efe80a756d23de62e7b3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":70,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>The omicron variant of the SARS-CoV-2 virus, discovered just a few weeks ago, is poised to dominate Covid-19 cases around the world. It’s a stunning new twist to the pandemic saga that has countries scrambling to prepare. In places like South Africa and the United Kingdom where omicron has been spreading fast, Covid-19 cases have doubled every three days or less. This includes people who were previously infected or vaccinated against Covid-19.</p></body></html>","htmlText":"<html><head></head><body><p>The omicron variant of the SARS-CoV-2 virus, discovered just a few weeks ago, is poised to dominate Covid-19 cases around the world. It’s a stunning new twist to the pandemic saga that has countries scrambling to prepare. In places like South Africa and the United Kingdom where omicron has been spreading fast, Covid-19 cases have doubled every three days or less. This includes people who were previously infected or vaccinated against Covid-19.</p></body></html>","text":"The omicron variant of the SARS-CoV-2 virus, discovered just a few weeks ago, is poised to dominate Covid-19 cases around the world. It’s a stunning new twist to the pandemic saga that has countries scrambling to prepare. In places like South Africa and the United Kingdom where omicron has been spreading fast, Covid-19 cases have doubled every three days or less. This includes people who were previously infected or vaccinated against Covid-19.","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":6,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698540563","repostId":2193127176,"repostType":4,"repost":{"id":"2193127176","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640345481,"share":"https://www.laohu8.com/m/news/2193127176?lang=&edition=full","pubTime":"2021-12-24 19:31","market":"us","language":"en","title":"Japan health panel approves Merck's oral COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2193127176","media":"Reuters","summary":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV","content":"<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan health panel approves Merck's oral COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan health panel approves Merck's oral COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","MRK":"默沙东","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4516":"特朗普概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193127176","content_text":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.\nThe panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.\nJapan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.\nIn addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill developed by Pfizer Inc. And Japan's Shionogi & Co is expected to soon file for approval of its own treatment supplying another 1 million doses by early next year.\nU.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.\nCountries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.\nJapan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":586,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":376,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":7116572,"commentId":"7116572","gmtCreate":1640574235622,"gmtModify":1640574235622,"authorId":9000000000000408,"author":{"id":9000000000000408,"idStr":"9000000000000408","authorId":9000000000000408,"name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698540563,"objectIdStr":"698540563","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Don't worry. The epidemic will be completely improved in 2022. Give up vaccine stocks and buy tourism stocks.","text":"Don't worry. The epidemic will be completely improved in 2022. Give up vaccine stocks and buy tourism stocks.","html":"Don't worry. The epidemic will be completely improved in 2022. Give up vaccine stocks and buy tourism stocks.","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":7116565,"commentId":"7116565","gmtCreate":1640574186938,"gmtModify":1640574186938,"authorId":9000000000000405,"author":{"id":9000000000000405,"idStr":"9000000000000405","authorId":9000000000000405,"name":"RubyPulitzer","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698540563,"objectIdStr":"698540563","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Vaccination benefits everyone in the world. The global economy needs recovery.","text":"Vaccination benefits everyone in the world. The global economy needs recovery.","html":"Vaccination benefits everyone in the world. The global economy needs recovery.","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":7116581,"commentId":"7116581","gmtCreate":1640574300429,"gmtModify":1640574300429,"authorId":9000000000000407,"author":{"id":9000000000000407,"idStr":"9000000000000407","authorId":9000000000000407,"name":"RonaldNixon","avatar":"https://static.tigerbbs.com/bc939ac6fbcb8985885a8a5671929aec","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698540563,"objectIdStr":"698540563","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Omicron's influence is growing. I am so worried.","text":"Omicron's influence is growing. I am so worried.","html":"Omicron's influence is growing. I am so worried.","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698540563"}